Roth Capital starts PlasmaTech Bio with Buy rating and $16 PT; shares up 11% premarket

• Micro cap PlasmaTech Biopharmaceuticals (PTBI) is up 11% premarket on robust volume in apparent response to Roth Capital's initiation of coverage with a Buy rating and $16 (108% upside) price target.
• Shares skyrocketed in early May after investors learned that hedge fund star George Soros established a stake in the company.
• Previously: PlasmaTech Bio up 43% premarket on Soros stake (May 5)